Summary | |
---|---|
Symbol | SV2B |
Name | synaptic vesicle glycoprotein 2B |
Aliases | KIAA0735; HsT19680; synaptic vesicle protein 2B homolog |
Chromosomal Location | 15q26.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane Multi-pass membrane protein Cytoplasmic vesicle, secretory vesicle, acrosome Note=Associated with synaptic-like microvesicles but not with insulin-containing vesicles in insulin-secreting cells of the pancreas (By similarity). Localizes to microvesicles in the pinealocytes. Localizes to the acrosome in spermatids (By similarity). |
Domain |
PF07690 Major Facilitator Superfamily PF13599 Pentapeptide repeats (9 copies) PF00083 Sugar (and other) transporter |
Function |
Probably plays a role in the control of regulated secretion in neural and endocrine cells. |
Biological Process |
GO:0001504 neurotransmitter uptake GO:0001505 regulation of neurotransmitter levels GO:0006836 neurotransmitter transport GO:0098657 import into cell |
Molecular Function | - |
Cellular Component |
GO:0001669 acrosomal vesicle GO:0008021 synaptic vesicle GO:0030133 transport vesicle GO:0030141 secretory granule GO:0030658 transport vesicle membrane GO:0030659 cytoplasmic vesicle membrane GO:0030672 synaptic vesicle membrane GO:0070382 exocytic vesicle GO:0097223 sperm part GO:0098793 presynapse GO:0099501 exocytic vesicle membrane GO:0099503 secretory vesicle |
KEGG |
hsa04512 ECM-receptor interaction |
Reactome |
R-HSA-1643685: Disease R-HSA-5663205: Infectious disease R-HSA-168799: Neurotoxicity of clostridium toxins R-HSA-5250968: Toxicity of botulinum toxin type A (BoNT/A) R-HSA-5250955: Toxicity of botulinum toxin type D (BoNT/D) R-HSA-5250992: Toxicity of botulinum toxin type E (BoNT/E) R-HSA-5250981: Toxicity of botulinum toxin type F (BoNT/F) R-HSA-5339562: Uptake and actions of bacterial toxins |
Summary | |
---|---|
Symbol | SV2B |
Name | synaptic vesicle glycoprotein 2B |
Aliases | KIAA0735; HsT19680; synaptic vesicle protein 2B homolog |
Chromosomal Location | 15q26.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between SV2B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | SV2B |
Name | synaptic vesicle glycoprotein 2B |
Aliases | KIAA0735; HsT19680; synaptic vesicle protein 2B homolog |
Chromosomal Location | 15q26.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of SV2B in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | SV2B |
Name | synaptic vesicle glycoprotein 2B |
Aliases | KIAA0735; HsT19680; synaptic vesicle protein 2B homolog |
Chromosomal Location | 15q26.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of SV2B in various data sets.
|
Points in the above scatter plot represent the mutation difference of SV2B in various data sets.
|
Summary | |
---|---|
Symbol | SV2B |
Name | synaptic vesicle glycoprotein 2B |
Aliases | KIAA0735; HsT19680; synaptic vesicle protein 2B homolog |
Chromosomal Location | 15q26.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SV2B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | SV2B |
Name | synaptic vesicle glycoprotein 2B |
Aliases | KIAA0735; HsT19680; synaptic vesicle protein 2B homolog |
Chromosomal Location | 15q26.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SV2B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SV2B. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | SV2B |
Name | synaptic vesicle glycoprotein 2B |
Aliases | KIAA0735; HsT19680; synaptic vesicle protein 2B homolog |
Chromosomal Location | 15q26.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SV2B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | SV2B |
Name | synaptic vesicle glycoprotein 2B |
Aliases | KIAA0735; HsT19680; synaptic vesicle protein 2B homolog |
Chromosomal Location | 15q26.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of SV2B expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | SV2B |
Name | synaptic vesicle glycoprotein 2B |
Aliases | KIAA0735; HsT19680; synaptic vesicle protein 2B homolog |
Chromosomal Location | 15q26.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between SV2B and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |